{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:13:30Z","timestamp":1789150410814,"version":"build-2803163510"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>This study aims to evaluate the safety, feasibility, effectiveness, and cost-saving potential of a shortened, vial-sharing outpatient blinatumomab regimen for treating relapsed or refractory (R\/R) ALL in children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>We conducted a retrospective study of pediatric patients with R\/R B-cell ALL (B-ALL) treated with a shortened outpatient blinatumomab regimen (&lt;21 days), aiming to achieve a negative measurable residual disease (MRD) remission before hematopoietic stem-cell transplantation (HSCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Twelve patients were included: three (25%) with primary refractory disease and nine (75%) with relapse. The median follow-up time was 33 months (range, 10-76 months). Blinatumomab was administered for a median of 19 days (range, 11-21), with 75% (9 of 12) of patients completing treatment entirely on an outpatient basis. Five patients (62%) achieved CR with undetectable MRD, and all four patients who initiated treatment because of persistent MRD achieved MRD clearance (100%). Ten patients (83%) proceeded to haploidentical HSCT. The estimated 3-year overall survival (OS) was 54%, and the relapse-free survival (RFS) was 44%. These optimization measures resulted in a 43% reduction in drug-related expenditures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Reduced-duration outpatient blinatumomab shows promise as a context-adapted strategy for heavily pretreated pediatric patients with ALL. Given the small retrospective cohort, these findings should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/go-25-00469","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T20:59:10Z","timestamp":1771621150000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL"],"prefix":"10.1200","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7933-094X","authenticated-orcid":true,"given":"Julia Esther","family":"Colunga Pedraza","sequence":"first","affiliation":[{"name":"Hematology Department, Facultad de Medicina y Hospital Universitario Dr Jos\u00e9 Eleuterio Gonz\u00e1lez, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-9345","authenticated-orcid":true,"given":"Andr\u00e9s","family":"G\u00f3mez-De Le\u00f3n","sequence":"additional","affiliation":[{"name":"Hematology Department, Facultad de Medicina y Hospital Universitario Dr Jos\u00e9 Eleuterio Gonz\u00e1lez, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-439X","authenticated-orcid":true,"given":"Perla Roc\u00edo","family":"Colunga Pedraza","sequence":"additional","affiliation":[{"name":"Hematology Department, Facultad de Medicina y Hospital Universitario Dr Jos\u00e9 Eleuterio Gonz\u00e1lez, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-4733","authenticated-orcid":true,"given":"Ingrid Gabriela","family":"L\u00f3pez Reyna","sequence":"additional","affiliation":[{"name":"Hematology Department, Facultad de Medicina y Hospital Universitario Dr Jos\u00e9 Eleuterio Gonz\u00e1lez, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Gabriela","family":"Mart\u00ednez Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hematology Department, Facultad de Medicina y Hospital Universitario Dr Jos\u00e9 Eleuterio Gonz\u00e1lez, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7988-8094","authenticated-orcid":true,"given":"Yahaira Valentina","family":"Jim\u00e9nez Antolinez","sequence":"additional","affiliation":[{"name":"Hematology Department, Facultad de Medicina y Hospital Universitario Dr Jos\u00e9 Eleuterio Gonz\u00e1lez, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Carlos","family":"Jaime-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Hematology Department, Facultad de Medicina y Hospital Universitario Dr Jos\u00e9 Eleuterio Gonz\u00e1lez, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-6427","authenticated-orcid":true,"given":"David","family":"G\u00f3mez Almaguer","sequence":"additional","affiliation":[{"name":"Hematology Department, Facultad de Medicina y Hospital Universitario Dr Jos\u00e9 Eleuterio Gonz\u00e1lez, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7638-5590","authenticated-orcid":true,"given":"\u00d3scar","family":"Gonz\u00e1lez Llano","sequence":"additional","affiliation":[{"name":"Hematology Department, Facultad de Medicina y Hospital Universitario Dr Jos\u00e9 Eleuterio Gonz\u00e1lez, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-790"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/23288604.2021.1914897"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2117119"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1255555"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02395-4"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2023.2209158"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004043"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4670-5"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020458"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0987"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107560"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30549"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00429"},{"key":"e_1_3_7_16_2","doi-asserted-by":"crossref","unstructured":"Philipp N Kazerani M Nicholls A et al: T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 140:1104\u20131118 2022","DOI":"10.1182\/blood.2022015956"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1187607"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70515"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005579"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29562"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34572"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28241"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27227"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T18:33:44Z","timestamp":1772562824000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1200\/GO-25-00469"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00469","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500469"}}